Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...

Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Key Takeaways AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue. The ...

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...